Andrea C Gore

About

Andrea C. Gore, Ph.D., is a Professor of Pharmacology & Toxicology and holds the Vacek Chair in Pharmacology at the University of Texas at Austin. Her work in the Gore Laboratory focuses on the effects of endocrine-disrupting chemicals (EDCs) on the neuroendocrine control of reproduction and behavior. Her current research involves using a rat model to understand how prenatal exposure to environmental endocrine disruptors alters the developing brain by inducing molecular and cellular changes in neurons within the hypothalamus and other brain regions. Beyond investigating the direct effects of EDCs on developing individuals, her research also explores how EDC exposures can lead to multigenerational behavioral changes through epigenetic actions on the germline and gametes, which are the precursors to ova and sperm, thereby affecting subsequent generations. Her team employs a variety of techniques, including behavioral, physiological, neuroanatomical, immunohistochemical, and molecular approaches such as gene expression, transcriptomics, epigenetic profiling, DNA methylation, RNAscope, and hormone assays.

Research topics

• Endocrinology
• Biology
• Medicine
• Internal medicine
• Neuroscience
• Intensive care medicine
• Psychology
• Bioinformatics
• Genetics

Selected publications

• Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

  The Lancet Diabetes & Endocrinology · 2023 · 102 citations

  BACKGROUND: The EMPA-KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. METHODS: , or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subg…

  DOI

• The Conflict between Regulatory Agencies over the 20,000-Fold Lowering of the Tolerable Daily Intake (TDI) for Bisphenol A (BPA) by the European Food Safety Authority (EFSA)

  Environmental Health Perspectives · 2024-04-01 · 47 citations

  articleOpen access

  BACKGROUND: . BPA is an extensively studied high production volume endocrine disrupting chemical (EDC) associated with a vast array of diseases. Prior risk assessments of BPA by EFSA as well as the US Food and Drug Administration (FDA) have relied on industry-funded studies conducted under good laboratory practice protocols (GLP) requiring guideline end points and detailed record keeping, while also claiming to examine (but rejecting) thousands of published findings by academic scientists. Guide…

  PublisherDOI

• Epigenetics, estrogenic endocrine-disrupting chemicals (EDCs), and the brain

  Advances in pharmacology · 2021 · 34 citations

  Senior authorCorresponding
  DOI

• Sex-specific effects of developmental exposure to polychlorinated biphenyls on neuroimmune and dopaminergic endpoints in adolescent rats

  Neurotoxicology and Teratology · 2020 · 28 citations

  DOI

• Regrettable Substitutes and the Brain: What Animal Models and Human Studies Tell Us about the Neurodevelopmental Effects of Bisphenol, Per- and Polyfluoroalkyl Substances, and Phthalate Replacements

  International Journal of Molecular Sciences · 2024-06-23 · 20 citations

  reviewOpen accessSenior authorCorresponding

  In recent decades, emerging evidence has identified endocrine and neurologic health concerns related to exposure to endocrine-disrupting chemicals (EDCs), including bisphenol A (BPA), certain per- and polyfluoroalkyl compounds (PFASs), and phthalates. This has resulted in consumer pressure to remove these chemicals from the market, especially in food-contact materials and personal care products, driving their replacement with structurally or functionally similar substitutes. However, these "new-…

  PublisherOA PDFDOI

Recent grants

• Functional and epigenetic effects of preconceptional EDCs on the female HPG axis

  NIH · $3.2M · 2019–2025

• NIH Grant R21ES012272

  NIH · $419k · 2007

• NIH Grant F32DK008743

  NIH · $81k

Frequent coauthors

• David Crews

  The University of Texas at Austin

  34 shared

• Lindsay M. Thompson

  The University of Texas at Austin

  25 shared

• Weiling Yin

  Jiangsu University

  22 shared

• Deena M. Walker

  Allen Institute for Brain Science

  22 shared

• Sarah M. Dickerson

  Walker (United States)

  16 shared

• Christoph Wanner

  University of Würzburg

  14 shared

• Martin Landray

  14 shared

• Ross Gillette

  The University of Texas at Austin

  14 shared

Education

• PhD, Neuroscience Training Program

  University of Wisconsin Madison

  1990

• A.B., Biology

  Princeton University

  1985

Similar researchers at University of Texas at Austin

• M Lynn Crismonh-67
• John Digiovannih-65
• Sharon DeMorrowh-60